Sector News

Bayer, Sensyne to form new AI ‘LifeHub’

October 10, 2019
Life sciences

Get involved in the discussion! Click here to comment on this story

Sensyne has announced a new partnership – its second this week – with Bayer, in order to accelerate the development of new treatments using clinical artificial intelligence.

The company revealed that it will work in partnership with the German pharma giant on novel projects at the LifeHub UK, including its inaugural project – the development of AI-enabled radiology to enhance patient outcomes.

LifeHub UK, which launches today, forms part of a global network of Bayer innovation hubs, designed to accelerate and optimise disease detection and data-driven drug discovery by enabling Artificial Intelligence (AI)-enabled imaging solutions.

The companies have announced that the first LifeHub UK project will focus on the development of AI-enabled radiology solutions using Sensyne Health’s proprietary clinical AI technology platform to identify digital solutions for automated image evaluation.

The project will analyse research from three million anonymised, ethically sourced NHS patient records and imaging data provided through Sensyne Health’s partnerships with NHS trusts, developing digital solutions to help radiologists improve the quality of the diagnosis and increase efficiency for patients receiving the right treatment in a timely manner.

Kemal Malik, Bayer board member for innovation, said that the company is “delighted to launch LifeHub UK,” and that it firmly believes “artificial intelligence has transformative potential for healthcare, leading to enhancements in prediction, prevention and personalised treatments.

“LifeHub UK’s roadmap is a perfect fit to Bayer’s Open Innovation strategy, which is designed to leverage places, programmes and partnerships – such as strategic alliances and joint ventures – in the life sciences fields of pharmaceuticals and agriculture.”

Earlier this week Sensyne announced a formal research agreement with the UK Medicines and Healthcare Products Regulatory Agency (MHRA), to contribute to the development of methods to validate software algorithms used in digital health.

The company is also already part of a partnership with the University of Oxford’s Big Data Institute (BDI), using data science and clinical artificial intelligence (clinical AI) for the patient-centred management and treatment of chronic disease.

By Anna Smith

Source: Pharma Times

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 11, 2019

Lupin sells off Japanese operation to tidy up its balance sheet

Life sciences

LinkedIn Twitter FacebookEven as other drugmakers are making big plays for business in Japan, India’s Lupin is backing off. Just weeks after selling the sterile manufacturing assets of its Kyowa […]

November 11, 2019

Novartis’ Sandoz, still working on U.S. slim-down, bets on Japan with Aspen deal

Life sciences

LinkedIn Twitter FacebookNovartis’ Sandoz has yet to nail down its generics selloff to Aurobindo Pharma, but that hasn’t stopped it from pursuing deals outside the troublesome U.S. market. The Novartis […]

November 8, 2019

Teva taps new CFO, hikes legal set-aside to more than $1B as opioid deal falters

Life sciences

LinkedIn Twitter FacebookAiming to settle the thousands of opioid lawsuits it faces, Teva has proposed an eye-popping $23 billion-plus deal with plaintiffs. So far, that offer hasn’t gained much traction, […]

Subscribe to our Weekly Newsletter

We're easy to reach